{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:29:37Z","timestamp":1794338977560,"version":"4.9.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Earlier studies led to the conclusion that human narcolepsy with cataplexy was correlated with the loss of hypocretin (Hcrt = orexin) neurons in the hypothalamus. We now report that individuals having narcolepsy with cataplexy also have an average 46% loss in the number and an 18% increase in the size of brainstem norepinephrine neurons in the locus coeruleus (LC), based on our analysis of 11 brains of individuals having narcolepsy with cataplexy. Microglial clustering around Hcrt neurons in the hypothalamus and around noradrenergic neurons in the locus coeruleus of individuals having narcolepsy with cataplexy indicates microglial involvement in the degeneration of both of these neuronal groups.<\/jats:p>","DOI":"10.1038\/s41467-026-70899-x","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:56:41Z","timestamp":1774713401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human narcolepsy is linked to degeneration of both locus coeruleus and hypocretin neurons"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-9545","authenticated-orcid":false,"given":"Thomas C.","family":"Thannickal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-8743","authenticated-orcid":false,"given":"Ming-Fung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia E.","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2898-0111","authenticated-orcid":false,"given":"Jerome M.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"70899_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437\u2013451 (1999).","journal-title":"Cell"},{"key":"70899_CR2","first-page":"2061","volume":"26","author":"TC Thannickal","year":"2000","unstructured":"Thannickal, T. C. et al. Human narcolepsy is linked to reduced number, size and synaptic bouton density in hypocretin-2 labeled neurons. Abstr. Soc. Neurosci. 26, 2061 (2000).","journal-title":"Abstr. Soc. Neurosci."},{"key":"70899_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469\u2013474 (2000).","journal-title":"Neuron"},{"key":"70899_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2301940","volume":"389","author":"Y Dauvilliers","year":"2023","unstructured":"Dauvilliers, Y. et al. Oral orexin receptor 2 agonist in narcolepsy type 1. N. Engl. J. Med. 389, 309\u2013321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"70899_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.sleep.2007.03.004","volume":"8","author":"M Thorpy","year":"2007","unstructured":"Thorpy, M. Therapeutic advances in narcolepsy. Sleep Med. 8, 427\u2013440 (2007).","journal-title":"Sleep Med."},{"key":"70899_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11940-015-0347-4","volume":"17","author":"M Thorpy","year":"2015","unstructured":"Thorpy, M. Update on therapy for narcolepsy. Curr. Treat. Options Neurol. 17, 1\u201312 (2015).","journal-title":"Curr. Treat. Options Neurol."},{"key":"70899_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991\u2013997 (2000).","journal-title":"Nat. Med."},{"key":"70899_CR8","doi-asserted-by":"crossref","unstructured":"Arand, D. L. & Bonnet, M. H. Chapter 26 - The multiple sleep latency test in Handbook of Clinical Neurology Clinical Neurophysiology: Basis and Technical Aspects (eds Levin, K. H. & Chauvel, P.) 393\u2013403 (Elsevier, 2019).","DOI":"10.1016\/B978-0-444-64032-1.00026-6"},{"key":"70899_CR9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.5665\/sleep.2080","volume":"35","author":"O Andlauer","year":"2012","unstructured":"Andlauer, O. et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 35, 1247\u20131255 (2012).","journal-title":"Sleep"},{"key":"70899_CR10","doi-asserted-by":"crossref","unstructured":"Barateau, L. et al. Cerebrospinal fluid monoamine levels in central hypersomnolence disorders. Sleep 44, zsab012p (2021).","DOI":"10.1093\/sleep\/zsab012"},{"key":"70899_CR11","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1021\/acs.analchem.9b02710","volume":"91","author":"K Bardsen","year":"2019","unstructured":"Bardsen, K. et al. Considerably lower levels of hypocretin-1 in cerebrospinal fluid is revealed by a novel mass spectrometry method compared with standard radioimmunoassay. Anal. Chem. 91, 9323\u20139329 (2019).","journal-title":"Anal. Chem."},{"key":"70899_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/s1389-9457(02)00191-0","volume":"4","author":"C Bassetti","year":"2003","unstructured":"Bassetti, C. et al. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med. 4, 7\u201312 (2003).","journal-title":"Sleep Med."},{"key":"70899_CR13","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.5665\/sleep.3756","volume":"37","author":"CR Baumann","year":"2014","unstructured":"Baumann, C. R. et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 37, 1035\u20131042 (2014).","journal-title":"Sleep"},{"key":"70899_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.euroneuro.2007.01.005","volume":"17","author":"L Brundin","year":"2007","unstructured":"Brundin, L., Bjorkqvist, M., Petersen, A. & Traskman-Bendz, L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 17, 573\u2013579 (2007).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"70899_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.5664\/jcsm.5604","volume":"12","author":"P Drakatos","year":"2016","unstructured":"Drakatos, P. & Leschziner, G. Cataplexy with normal sleep studies and normal CSF hypocretin: an explanation? J. Clin. Sleep Med. 12, 449\u2013450 (2016).","journal-title":"J. Clin. Sleep Med."},{"key":"70899_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.sleep.2014.02.005","volume":"15","author":"MS Heier","year":"2014","unstructured":"Heier, M. S., Skinningsrud, A., Paus, E. & Gautvik, K. M. Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy. Sleep Med. 15, 614\u2013618 (2014).","journal-title":"Sleep Med."},{"key":"70899_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep25162","volume":"6","author":"C Hirtz","year":"2016","unstructured":"Hirtz, C. et al. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci. Rep. 6, 25162 (2016).","journal-title":"Sci. Rep."},{"key":"70899_CR18","doi-asserted-by":"crossref","unstructured":"Vialaret, J. et al. 16-mer hypocretin-1\/orexin-A in cerebrospinal fluid to diagnose narcolepsy. Sleep 48, zsaf237 (2025).","DOI":"10.1093\/sleep\/zsaf237"},{"key":"70899_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(04)15951-5","volume":"363","author":"R Khatami","year":"2004","unstructured":"Khatami, R. et al. Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. Lancet 363, 1199\u20131200 (2004).","journal-title":"Lancet"},{"key":"70899_CR20","doi-asserted-by":"crossref","unstructured":"Knudsen, S. et al. Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis. Mult. Scler. 14, 734\u2013738 (2008).","DOI":"10.1177\/1352458508088939"},{"key":"70899_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.clinbiochem.2021.01.009","volume":"90","author":"M Lindstrom","year":"2021","unstructured":"Lindstrom, M. et al. Orexin-A measurement in narcolepsy: a stability study and a comparison of LC-MS\/MS and immunoassays. Clin. Biochem. 90, 34\u201339 (2021).","journal-title":"Clin. Biochem."},{"key":"70899_CR22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553\u20131562 (2002).","journal-title":"Arch. Neurol."},{"key":"70899_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39\u201341 (2000).","journal-title":"Lancet"},{"key":"70899_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ana.1130","volume":"50","author":"S Nishino","year":"2001","unstructured":"Nishino, S. et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 50, 381\u2013388 (2001).","journal-title":"Ann. Neurol."},{"key":"70899_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","volume":"9","author":"S Nishino","year":"2005","unstructured":"Nishino, S. & Kanbayashi, T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system. Sleep Med. Rev. 9, 269\u2013310 (2005).","journal-title":"Sleep Med. Rev."},{"key":"70899_CR26","doi-asserted-by":"publisher","first-page":"zsab285","DOI":"10.1093\/sleep\/zsab285","volume":"45","author":"E Postiglione","year":"2022","unstructured":"Postiglione, E. et al. Narcolepsy with intermediate cerebrospinal level of hypocretin-1. Sleep 45, zsab285 (2022).","journal-title":"Sleep"},{"key":"70899_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/ana.10164","volume":"51","author":"A Schuld","year":"2002","unstructured":"Schuld, A., Blum, W. F. & Pollmacher, T. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 51, 660\u2013661 (2002).","journal-title":"Ann. Neurol."},{"key":"70899_CR28","doi-asserted-by":"crossref","unstructured":"van der Hoeven, A. E. et al. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1. Sleep 45, zsac052 (2022).","DOI":"10.1093\/sleep\/zsac052"},{"key":"70899_CR29","doi-asserted-by":"crossref","unstructured":"van der Hoeven, A. E. et al. Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification. Sleep 45, zsac103 (2022).","DOI":"10.1093\/sleep\/zsac103"},{"key":"70899_CR30","doi-asserted-by":"crossref","unstructured":"Wasserman, D., Bassetti, C. L. A., & Rosenzweig, I. Narcolepsy with resolution of cataplexy and persisting orexin deficiency. J. Clin. Sleep Med. 16, 1383\u20131386 (2020).","DOI":"10.5664\/jcsm.8572"},{"key":"70899_CR31","doi-asserted-by":"crossref","unstructured":"Farahani, F., Anaclet, C., Azizi, H., & Gompf, H. S. The locus coeruleus, a blue spot for early diagnosis and prognosis of Alzheimer\u2019s disease. Front. Aging Neurosci. 17, 2025, (2025).","DOI":"10.3389\/fnagi.2025.1632236"},{"key":"70899_CR32","doi-asserted-by":"publisher","first-page":"s438","DOI":"10.2741\/1074","volume":"8","author":"BE Jones","year":"2003","unstructured":"Jones, B. E. Arousal systems. Front Biosci. 8, s438\u2013s451 (2003).","journal-title":"Front Biosci."},{"key":"70899_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41386-019-0444-2","volume":"45","author":"BE Jones","year":"2020","unstructured":"Jones, B. E. Arousal and sleep circuits. Neuropsychopharmacology 45, 6\u201320 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"70899_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0006-8993(77)90378-X","volume":"127","author":"BE Jones","year":"1977","unstructured":"Jones, B. E. & Moore, R. Y. Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res. 127, 23\u201353 (1977).","journal-title":"Brain Res."},{"key":"70899_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.conb.2017.03.018","volume":"44","author":"BE Jones","year":"2017","unstructured":"Jones, B. E. Principal cell types of sleep\u2212wake regulatory circuits. Curr. Opin. Neurobiol. 44, 101\u2013109 (2017).","journal-title":"Curr. Opin. Neurobiol."},{"key":"70899_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41583-020-0360-9","volume":"21","author":"GR Poe","year":"2020","unstructured":"Poe, G. R. et al. Locus coeruleus: a new look at the blue spot. Nat. Rev. Neurosci. 21, 644\u2013659 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"70899_CR37","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0306-4522(98)00600-9","volume":"91","author":"MF Wu","year":"1999","unstructured":"Wu, M. F. et al. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 91, 1389\u20131399 (1999).","journal-title":"Neuroscience"},{"key":"70899_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pneurobio.2005.02.001","volume":"75","author":"H Fedorow","year":"2005","unstructured":"Fedorow, H. et al. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson\u2019s disease. Prog. Neurobiol. 75, 109\u2013124 (2005).","journal-title":"Prog. Neurobiol."},{"key":"70899_CR39","doi-asserted-by":"crossref","unstructured":"Elstner, M. et al. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol. Brain 4, 43 (2011).","DOI":"10.1186\/1756-6606-4-43"},{"key":"70899_CR40","first-page":"360","volume":"38","author":"Y Honda","year":"1984","unstructured":"Honda, Y., Doi, Y., Juji, T. & Satake, M. Narcolepsy and HLA: Positive DR2 as a prerequisite for the development of narcolepsy. Folia Psychiatr. Neurol. Jpn. 38, 360 (1984).","journal-title":"Folia Psychiatr. Neurol. Jpn."},{"key":"70899_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/sleep\/9.1.133","volume":"9","author":"Y Honda","year":"1986","unstructured":"Honda, Y. et al. HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy. Sleep 9, 133\u2013142 (1986).","journal-title":"Sleep"},{"key":"70899_CR42","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","volume":"34","author":"S Tabuchi","year":"2014","unstructured":"Tabuchi, S. et al. Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J. Neurosci. 34, 6495\u20136509 (2014).","journal-title":"J. Neurosci."},{"key":"70899_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","volume":"98","author":"L Lin","year":"1999","unstructured":"Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor gene. Cell 98, 365\u2013376 (1999).","journal-title":"Cell"},{"key":"70899_CR44","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2460\/javma.1976.168.11.1036","volume":"168","author":"MM Mitler","year":"1976","unstructured":"Mitler, M. M., Soave, O. & Dement, W. C. Narcolepsy in seven dogs. J. Am. Vet. Med. Ass. 168, 1036\u20131038 (1976).","journal-title":"J. Am. Vet. Med. Ass."},{"key":"70899_CR45","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1073\/pnas.88.8.3475","volume":"88","author":"E Mignot","year":"1991","unstructured":"Mignot, E. et al. Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin chain switch-like segment. Proc. Natl. Acad. Sci. USA 88, 3475\u20133478 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70899_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1474-4422(21)00368-9","volume":"21","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers, Y. et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.  Lancet Neurol. 21, 53\u201365 (2022).","journal-title":"Lancet Neurol."},{"key":"70899_CR47","doi-asserted-by":"crossref","unstructured":"Mayer, G. et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a post-authorization, non-interventional surveillance study. Sleep 41, zsy128 (2018).","DOI":"10.1093\/sleep\/zsy128"},{"key":"70899_CR48","doi-asserted-by":"crossref","unstructured":"Wu, M. F. et al. Effects of sodium oxybate on hypocretin\/orexin and locus coeruleus neurons. Sleep 46, zsad135 (2023).","DOI":"10.1093\/sleep\/zsad135"},{"key":"70899_CR49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.neuron.2005.04.035","volume":"46","author":"BY Mileykovskiy","year":"2005","unstructured":"Mileykovskiy, B. Y., Kiyashchenko, L. I. & Siegel, J. M. Behavioral correlates of activity in identified hypocretin\/orexin neurons. Neuron 46, 787\u2013798 (2005).","journal-title":"Neuron"},{"key":"70899_CR50","first-page":"492","volume":"149","author":"MF Wu","year":"2011","unstructured":"Wu, M. F., Nienhuis, R., Maidment, N., Lam, H. A. & Siegel, J. M. Cerebrospinal fluid hypocretin (orexin) levels are elevated by play but are not raised by exercise and its associated heart rate, blood pressure, respiration or body temperature changes. Arch. Ital. Biol. 149, 492\u2013498 (2011).","journal-title":"Arch. Ital. Biol."},{"key":"70899_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2461","volume":"4","author":"AM Blouin","year":"2013","unstructured":"Blouin, A. M. et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat. Commun. 4, 1547 (2013).","journal-title":"Nat. Commun."},{"key":"70899_CR52","doi-asserted-by":"publisher","unstructured":"Thannickal, T. C. et al. Opiates increase the number of hypocretin-producing cells in mouse and human brain, and reverse cataplexy in a mouse model of narcolepsy. Sci. Transl. Med. 10, pii: eaao4953-https:\/\/doi.org\/10.1126\/scitranslmed.aao4953 (2018).","DOI":"10.1126\/scitranslmed.aao4953"},{"key":"70899_CR53","doi-asserted-by":"publisher","first-page":"e0563252025","DOI":"10.1523\/JNEUROSCI.0563-25.2025","volume":"45","author":"EA Berry","year":"2025","unstructured":"Berry, E. A. et al. Repeated morphine exposure reversibly impairs spike generation and repetitive firing in a functionally distinct subpopulation of orexin neurons.  J. Neurosci. 45, e0563252025 (2025).","journal-title":"J. Neurosci."},{"key":"70899_CR54","doi-asserted-by":"crossref","unstructured":"McGregor, R., Wu, M. F., Thannickal, T. C., Li, S., & Siegel, J. M. Opioid-induced neuroanatomical, microglial and behavioral changes are blocked by suvorexant without diminishing opioid analgesia. Nat. Mental Health 9, 1018\u20131031 (2024).","DOI":"10.1038\/s44220-024-00278-2"},{"key":"70899_CR55","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.neuroscience.2010.06.009","volume":"169","author":"K Takahashi","year":"2010","unstructured":"Takahashi, K., Kayama, Y., Lin, J. S. & Sakai, K. Locus coeruleus neuronal activity during the sleep-waking cycle in mice. Neuroscience 169, 1115\u20131126 (2010).","journal-title":"Neuroscience"},{"key":"70899_CR56","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1523\/JNEUROSCI.0454-15.2015","volume":"35","author":"C Varazzani","year":"2015","unstructured":"Varazzani, C., San-Galli, A., Gilardeau, S. & Bouret, S. Noradrenaline and dopamine neurons in the reward\/effort trade-off: a direct electrophysiological comparison in behaving monkeys. J. Neurosci. 35, 7866\u20137877 (2015).","journal-title":"J. Neurosci."},{"key":"70899_CR57","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.brainres.2015.12.010","volume":"1641","author":"GA Zitnik","year":"2016","unstructured":"Zitnik, G. A. Control of arousal through neuropeptide afferents of the locus coeruleus. Brain Res. 1641, 338\u2013350 (2016).","journal-title":"Brain Res."},{"key":"70899_CR58","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1152\/jn.00528.2010","volume":"104","author":"YY Lai","year":"2010","unstructured":"Lai, Y. Y., Kodama, T., Schenkel, E. & Siegel, J. M. Behavioral response and transmitter release during atonia elicited by medial medullary stimulation. J. Neurophysiol. 104, 2024\u20132033 (2010).","journal-title":"J. Neurophysiol."},{"key":"70899_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/sleep\/34.1.99","volume":"34","author":"S Bayard","year":"2011","unstructured":"Bayard, S. et al. Decision making in narcolepsy with cataplexy. Sleep 34, 99\u2013104 (2011).","journal-title":"Sleep"},{"key":"70899_CR60","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1177\/0269881106082899","volume":"7","author":"P Feng","year":"2008","unstructured":"Feng, P., Vurbic, D., Wu, Z., Hu, Y. & Strohl, K. P. Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J. Psychopharmacol. 7, 784\u2013791 (2008).","journal-title":"J. Psychopharmacol."},{"key":"70899_CR61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.sleep.2013.08.798","volume":"15","author":"CO Inocente","year":"2014","unstructured":"Inocente, C. O. et al. Depressive feelings in children with narcolepsy. Sleep Med. 15, 309\u2013314 (2014).","journal-title":"Sleep Med."},{"key":"70899_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.sleep.2017.07.022","volume":"39","author":"MJ Lee","year":"2017","unstructured":"Lee, M. J. et al. Comorbidity of narcolepsy and depressive disorders: a nationwide population-based study in Taiwan. Sleep Med. 39, 95\u2013100 (2017).","journal-title":"Sleep Med."},{"key":"70899_CR63","doi-asserted-by":"crossref","unstructured":"Lu, J. et al. Sexually dimorphic changes of hypocretin (orexin) in depression. eBioMedicine 18, 311\u2013319 (2017).","DOI":"10.1016\/j.ebiom.2017.03.043"},{"key":"70899_CR64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neulet.2010.07.038","volume":"483","author":"FM Schmidt","year":"2010","unstructured":"Schmidt, F. M. et al. Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci. Lett. 483, 20\u201322 (2010).","journal-title":"Neurosci. Lett."},{"key":"70899_CR65","doi-asserted-by":"crossref","unstructured":"Guilleminault, C. & Cao, M. T. Narcolepsy: diagnosis and management. in Principles and Practice of Sleep Medicine (eds Kryger, M. H., Roth, T. & Dement, W. C.) 957\u2013968 (Elsevier Saunders, Missouri, 2011).","DOI":"10.1016\/B978-1-4160-6645-3.00085-2"},{"key":"70899_CR66","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/0014-4886(74)90122-8","volume":"45","author":"MM Mitler","year":"1974","unstructured":"Mitler, M. M., Boyson, B. G., Campbell, L. & Dement, W. C. Narcolepsy-cataplexy in a female dog. Exp. Neurol. 45, 332\u2013340 (1974).","journal-title":"Exp. Neurol."},{"key":"70899_CR67","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996\u201310015 (1998).","journal-title":"J. Neurosci."},{"key":"70899_CR68","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1523\/JNEUROSCI.0080-14.2014","volume":"34","author":"SW Black","year":"2014","unstructured":"Black, S. W. et al. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J. Neurosci. 34, 6485\u20136494 (2014).","journal-title":"J. Neurosci."},{"key":"70899_CR69","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/sleep\/27.5.899","volume":"27","author":"P Meerlo","year":"2004","unstructured":"Meerlo, P., Westerveld, P., Turek, F. W. & Koehl, M. Effects of gamma-hydroxybutyrate (GHB) on vigilance states and EEG in mice. Sleep 27, 899\u2013904 (2004).","journal-title":"Sleep"},{"key":"70899_CR70","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","volume":"24","author":"O Larrosa","year":"2001","unstructured":"Larrosa, O., de la Llave, Y., Barrio, S., Granizo, J. J. & Garcia-Borreguero, D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study on reboxetine. Sleep 24, 282\u2013285 (2001).","journal-title":"Sleep"},{"key":"70899_CR71","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pneurobio.2009.07.004","volume":"89","author":"M Mamelak","year":"2009","unstructured":"Mamelak, M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog. Neurobiol. 89, 193\u2013219 (2009).","journal-title":"Prog. Neurobiol."},{"key":"70899_CR72","doi-asserted-by":"crossref","unstructured":"Yan, Z. et al. Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis. BMC Neurol. 25, 466 (2025).","DOI":"10.1186\/s12883-025-04328-9"},{"key":"70899_CR73","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.neurobiolaging.2010.12.008","volume":"33","author":"TE Scammell","year":"2011","unstructured":"Scammell, T. E., Matheson, J. K., Honda, M., Thannickal, T. C. & Siegel, J. M. Coexistence of narcolepsy and Alzheimer\u2019s disease. Neurobiol. Aging 33, 1318\u20131319 (2011).","journal-title":"Neurobiol. Aging"},{"key":"70899_CR74","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ana.26300","volume":"91","author":"L Shan","year":"2022","unstructured":"Shan, L., Balesar, R., Swaab, D. F., Lammers, G. J. & Fronczek, R. Reduced numbers of corticotropin-releasing hormone neurons in narcolepsy type 1. Ann. Neurol. 91, 282\u2013288 (2022).","journal-title":"Ann. Neurol."},{"key":"70899_CR75","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ana.23968","volume":"74","author":"J John","year":"2013","unstructured":"John, J. et al. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann. Neurol. 74, 786\u2013793 (2013).","journal-title":"Ann. Neurol."},{"key":"70899_CR76","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ana.24019","volume":"74","author":"PO Valko","year":"2013","unstructured":"Valko, P. O. et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann. Neurol. 74, 794\u2013804 (2013).","journal-title":"Ann. Neurol."},{"key":"70899_CR77","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"308","author":"P Davies","year":"1976","unstructured":"Davies, P. & Maloney, A. J. F. Selective loss of central cholinergic neurons in Alzheimer\u2019s disease.  Lancet 308, 1403 (1976).","journal-title":"Lancet"},{"key":"70899_CR78","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(25)01294-2","volume":"406","author":"GB Frisoni","year":"2025","unstructured":"Frisoni, G. B. et al. New landscape of the diagnosis of Alzheimer\u2019s disease.  Lancet 406, 1389\u20131407 (2025).","journal-title":"Lancet"},{"key":"70899_CR79","doi-asserted-by":"crossref","unstructured":"Drissi, N. M. et al. Structural anomaly in the reticular formation in narcolepsy type 1, suggesting lower levels of neuromelanin. NeuroImage Clin. 23, 101875 (2019).","DOI":"10.1016\/j.nicl.2019.101875"},{"key":"70899_CR80","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/mds.27776","volume":"34","author":"M Vila","year":"2019","unstructured":"Vila, M. Neuromelanin, aging, and neuronal vulnerability in Parkinson\u2019s disease. Mov. Disord. 34, 1440\u20131451 (2019).","journal-title":"Mov. Disord."},{"key":"70899_CR81","doi-asserted-by":"crossref","unstructured":"Deng, J. et al. Emerging roles of microglia depletion in the treatment of spinal cord injury. Cells 11, 1871 (2022).","DOI":"10.3390\/cells11121871"},{"key":"70899_CR82","unstructured":"Mai, J. K., Assheuer, J., & Paxinos, G. Atlas of the Human Brain (Elsevier Academic Press, 2004)."},{"key":"70899_CR83","unstructured":"Paxinos, G. & Franklin, K. B. J. Paxinos and Franklin\u2019s the Mouse Brain in Stereotaxic Coordinates (Academic Press, 2019)."},{"key":"70899_CR84","unstructured":"Lim, R. K., Liu, C.-N., & Moffit, R. L. Stereotaxic Atlas of the Dog\u2019s Brain (Charles C Thomas, Springfield Illinois, 1960)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70899-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70899-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70899-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:02:52Z","timestamp":1780617772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70899-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70899"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70899-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4978"}}